All In Biotech

Drug Trial Radar · NCT04777357

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 Years of Age) in the Treatment of Depressive Episodes Associated With Bipolar I Disorder

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 338 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

338

Planned (sponsor's estimate)

Start

Apr 28, 2021

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population. Cariprazine is an approved drug for the treatment of depressive episodes in adult participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 338 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites in the US and Puerto Rico. Participants receiving the study drug will receive Dose A or B of Cariprazine based on age and weight. At Week 3, participants with insufficient response will have their dose increased to Dose B or Dose C, while participants with sufficient response will continue receiving the Dose A or B for the remainder of the treatment period. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Depression
  • Bipolar I Disorder

Interventions

  • CariprazineDrug

    Oral Capsule

  • PlaceboDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Baseline (Week 0) to Week 10
  2. Abnormal Change from Baseline in Vital SignsTime frame: Baseline (Week 0) to Week 10
  3. Number of Participants with Incidence of Abnormal Clinical Laboratory Test ResultsTime frame: Baseline (Week 0) to Week 6
  4. Change in Electrocardiogram (ECG)Time frame: Baseline (Week 0) to Week 6
  5. Change From Baseline in Simpson-Angus Scale (SAS)Time frame: Baseline (Week 0) to Week 6
  6. Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline (Week 0) to Week 10
  7. Change From Baseline in Barnes Akathisia Rating Scale (BARS)Time frame: Baseline (Week 0) to Week 6
  8. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)Time frame: Baseline (Week 0) to Week 6
  9. Change in Children's Depression Rating Scale - Revised (CDRS-R) Total ScoreTime frame: Baseline (Week 0) to Week 6

Locations

87 sites in 3 countries. Site status is shown where the registry gives one.

  • Pillar Clinical Research /ID# 226504

    Bentonville, Arkansas · Completed

  • Advanced Research Center /ID# 227073

    Anaheim, California · Recruiting

  • Care Access Research /ID# 226316

    Beverly Hills, California · Completed

  • Inland Pyschiatric Medical Group - Chino /ID# 278667

    Chino, California · Recruiting

  • ProScience Research Group /ID# 226223

    Culver City, California · Completed

  • National Institute of Clinical Research - Garden Grove /ID# 262835

    Garden Grove, California · Completed

  • Accellacare - Long Beach /ID# 279482

    Long Beach, California · Recruiting

  • Duplicate_Alliance for Research - Long Beach /ID# 226522

    Long Beach, California · Completed

  • Atp Clinical Research - Orange /ID# 253719

    Orange, California · Completed

  • CHOC Children's Hospital /ID# 260298

    Orange, California · Recruiting

  • Prospective Research Innovations Inc /ID# 240774

    Rancho Cucamonga, California · Completed

  • Inland Psychiatric Medical Group /ID# 274621

    Redlands, California · Recruiting

  • University of California Davis Health /ID# 268306

    Sacramento, California · Recruiting

  • University of California, San Diego Department of Psychiatry /ID# 226463

    San Diego, California · Completed

  • Lumos Clinical Research Center /ID# 262805

    San Jose, California · Completed

  • Pacific Clinical Research Management Group /ID# 227075

    Upland, California · Completed

  • Kinetic Clinical Research /ID# 277152

    West Covina, California · Recruiting

  • D&H Doral Research Center-Doral /ID# 255458

    Doral, Florida · Recruiting

  • Advanced Research Institute of Miami /ID# 228222

    Homestead, Florida · Completed

  • Innovus Clinical Research /ID# 282255

    Kissimmee, Florida · Recruiting

  • Columbus Clinical Services, Llc /Id# 229792

    Miami, Florida · Completed

  • G+C Research Group, LLC /ID# 261399

    Miami, Florida · Completed

  • Florida Research Center, Inc. /ID# 240775

    Miami, Florida · Recruiting

  • South Florida Research Ph I-IV /ID# 240778

    Miami Springs, Florida · Completed

  • Medical Research Group of Central Florida /ID# 256757

    Orange City, Florida · Completed

  • APG Research, LLC /ID# 226519

    Orlando, Florida · Completed

  • Nova Psychiatry Inc. /ID# 270892

    Orlando, Florida · Completed

  • Panhandle Research and Medical Clinic, LLC /ID# 268522

    Pensacola, Florida · Completed

  • D&H Tamarac Research Center /ID# 250434

    Tamarac, Florida · Recruiting

  • University of South Florida- Neuroscience Institute /ID# 246508

    Tampa, Florida · Completed

  • Atlanta Center for Medical Research /ID# 226480

    Atlanta, Georgia · Completed

  • CenExcel iResearch LLC /ID# 228695

    Decatur, Georgia · Completed

  • Atlanta Behavioral Research, LLC /ID# 226486

    Dunwoody, Georgia · Completed

  • Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 226371

    Stockbridge, Georgia · Completed

  • Denali Health Atlanta, LLC /ID# 278167

    Stone Mountain, Georgia · Recruiting

  • Duplicate_Ascension St. Elizabeth /ID# 240772

    Chicago, Illinois · Completed

  • Baber Research Group /ID# 232279

    Naperville, Illinois · Completed

  • Advanced Quality Medical Research /ID# 272902

    Orland Park, Illinois · Recruiting

  • Indiana University /ID# 260705

    Indianapolis, Indiana · Completed

  • Benchmark Research /ID# 260714

    Shreveport, Louisiana · Completed

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.